A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B

Trial Profile

A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs SB FIX (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; First in man
  • Sponsors Sangamo Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Jan 2017 According to a Sangamo BioSciences media release, data from this study is expected in late 2017 or early 2018.
    • 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top